Risk factors for cardiovascular complications in COVID-19 patients

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Objective of the study. To study literature data on cardiovascular complications risk assessment, their prevention and treatment in patients with new coronavirus infection (COVID 19) and various comorbid diseases.

Material and methods. The authors analyzed 19 Russian and 11 foreign publications that addressed the issues of risk assessment of cardiovascular complications, their prevention and treatment in patients with new coronavirus infection (COVID 19) and various comorbid conditions.

Results. Cardiovascular disease is the most common comorbid pathology in COVID 19 patients. Fatal complications in COVID-19 are associated with pulmonary embolism, acute coronary syndrome, and acute cerebral circulation disorder. Respiratory failure and worsening of the clinical course of existing cardiovascular diseases in patients could be the cause of death in patients with new coronavirus infection. The presence of previous myocardial infarction in men and women with COVID-19 increased the risk of death by 3-fold.

Conclusion. The lethality of patients with COVID-19 in the presence of coronary heart disease, arterial hypertension, obesity, and diabetes mellitus was higher than in the absence of the above pathology. COVID-19 disease is associated with an increased risk of cardiovascular complications. The examination of patients with COVID-19 requires thorough analysis of cardiovascular and comorbid risk factors with subsequent correction of therapeutic, preventive and rehabilitative measures.

Full Text

Restricted Access

About the authors

Andrey N. Kovalchuk

Branch № 7 of the Federal State Institution 1586 Military Clinical Hospital of the Ministry of Defense of Russia

Author for correspondence.
Email: akovalchuk69@rambler.ru

cardiologist, general practitioner, deputy chief

Russian Federation, Tver, Peterburgskoe Shosse, 3

References

  1. Avdeev S.N., Adamyan L. V., Alexeeva E. I. [et al]. Prevention, diagnosis and treatment of new coronavirus infection (COVID-19): Provisional guidelines. Moscow: Ministry of Health of the Russian Federation. 2021; 233p.
  2. Bubnova M.G., Shlyakhto E.V., Aronov D.M. [et al]. A new coronavirus infectious disease COVID-19: features of complex cardiac and respiratory rehabilitation. Russian Journal of Cardiology. 2021; 26(5):183–222. doi: 10.15829/1560-4071-2021-4487.
  3. Oganov R.G., Simanenkov V.I., Bakulin I.G. et al. Comorbid pathology in clinical practice. Algorithms of diagnostics and treatment. Cardiovascular therapy and prevention. 2019;18(1):5–66. https://doi.org/10.15829/1728-8800-2019-1-5-66
  4. Dedov DV, Mazaev VP, Ryazanova SV et al. Study of quality of life in interventional and conservative treatment of patients with stable angina pectoris at long-term follow-up. Cardiovascular Therapy and Prevention. 2014;13(5):31–35. doi: 10.15829/1728-8800-2014-5-31-35
  5. Arutyunov A.G., Seferovich P., Bakulin I. G. [et al]. Rehabilitation after COVID-19. Resolution of the International Council of Experts of the Eurasian Association of Physicians and the Russian Cardiology Society. Russian Journal of Cardiology. 2021; 26(9): 135–151. doi: 10.15829/1560-4071-2021-4694.
  6. Dedov D.V. New coronavirus infection: clinical and pathogenetic aspects, prevention, importance of vitamins and trace elements. Phys. 2022; 33(2): 47–49. doi: 10.29296/25877305-2022-02-07.
  7. Dedov D., Mukailov N., Evtyukhin I. Quality of life and prognosis in patients with AH and CHD with atrial fibrillation. Phys. 2013; 7:72–74.
  8. Sokolova N.A., Arefiev M.N., Grishina I.S. et al. Features of the clinic, diagnosis and treatment of patients with cardiovascular pathology in the context of coronavirus infection. Diagnosis and treatment of new coronavirus infection. Organization of work in the conditions of a multidisciplinary hospital: Manual for physicians / Edited by V.I. Vechorko. Moscow: OOO «Publishing House «Practice». 2020. 208–217. doi: 10.51833/9785898161804_208.
  9. Dedov D.V., Ivanov A.P., Elgardt I.A. Effect of electromechanical remodeling of the heart on the development of atrial fibrillation in patients with CHD and arterial hypertension. Russian Journal of Cardiology. 2011; 16(4):13–18.
  10. Barbarash OL, Karetnikova VN, Kashtalap VV, et al. A new coronavirus disease (COVID-19) and cardiovascular disease. Comprehensive problems of cardiovascular disease. 2020; 9(2):17–28. doi: 10.17802/2306-1278-2020-9-2-17-28.
  11. Dedov D., Mukailov N., Evtyukhin I. Combination of amlodipine and atorvastatin in reducing the risk of cardiovascular complications. Phys. 2013; 3: 18–19.
  12. Martsevich S.Y., Lukyanov M.M., Pulin A.A. et al. Prehospital period in COVID-19 patients: cardiovascular comorbidity and pharmacotherapy of cardiovascular diseases during the first epidemic wave (hospital registry data). Rational pharmacotherapy in cardiology. 2021; 17(6): 873–879. doi: 10.20996/1819-6446-2021-12-13.
  13. Vakhnenko Y.V., Korotkikh A.V., Bagdasarian E.A. Myocardial damage in new coronavirus infection (literature review). Bulletin of Respiratory Physiology and Pathology. 2021; 82: 129–145. doi: 10.36604/1998-5029-2021-82-129-145.
  14. Seyed Hosseini E., Riahi Kashani N., Nikzad H. et al. The novel coronavirus Disease-2019 (COVID-19): Mechanism of action, detection and recent therapeutic strategies. Virology. 2020; 551:1–9. doi: 10.1016/j.virol.2020.08.011.
  15. Majumder J., Minko T. Recent Developments on Therapeutic and Diagnostic Approaches for COVID-19. AAPS J. 2021;23(1):14. doi: 10.1208/s12248-020-00532-2.
  16. Krittanawong C., Kumar A., Hahn J. et al. Cardiovascular risk and complications associated with COVID-19. Am J Cardiovasc Dis. 2020; 15;10(4):479–489.
  17. Dedov D.V. New coronavirus infection: clinical and pathogenetic aspects, prevention, importance of vitamins and trace elements. Phys. 2022; 33(2): 47–49. doi: 10.29296/25877305-2022-02-07.
  18. Szarpak L., Mierzejewska M., Jurek J. et al. Effect of Coronary Artery Disease on COVID-19-Prognosis and Risk Assessment: A Systematic Review and Meta-Analysis. Biology (Basel). 2022;11(2):221. doi: 10.3390/biology11020221.
  19. Palakshappa J.A., Krall J.T.W., Belfield L.T. et al. Long-Term Outcomes in Acute Respiratory Distress Syndrome: Epidemiology, Mechanisms, and Patient Evaluation. Crit Care Clin. 2021;37(4):895–911. doi: 10.1016/j.ccc.2021.05.010.
  20. Dedov D.V., Marchenko S.D. Vitamins, iron, zinc, selenium and selenium-containing drugs in the comprehensive prevention of complications and treatment of COVID-19 patients. Pharmacia. 2022; 71(1): С. 5–9. doi: 10.29296/25419218-2022-01-01.
  21. Alqahtani M.S., Abbas M., Alsabaani A. et al. The Potential Impact of COVID-19 Virus on the Heart and the Circulatory System. Infect Drug Resist. 2022; 15:1175–1189. doi: 10.2147/IDR.S351318.
  22. Dedov D., Mukailov N., Evtyukhin I. Combination of amlodipine and atorvastatin in reducing the risk of cardiovascular complications. Phys. 2013; 3: 18–19.
  23. Szarpak L., Jaguszewski M.J., Pruc M. et al. Myocardial injury: a future challenge for long-COVID-19 complications. Eur Heart J Qual Care Clin Outcomes. 2021;7(6):618. doi: 10.1093/ehjqcco/qcab067.
  24. Dedov D, Mukailov N, Evtyukhin I. Potassium and magnesium preparations in the comprehensive prevention of complications of arterial hypertension and ischemic heart disease. Phys. 2013; 8:45–46.
  25. Atzrodt C.L., Maknojia I., McCarthy R.D.P. et al. Guide to COVID-19: a global pandemic caused by the novel coronavirus SARS-CoV-2. FEBS J. 2020; 287(17):3633–3650. doi: 10.1111/febs.15375.
  26. Dedov D., Mukailov N., Evtyukhin I. et al. Preduktal MB in the treatment and prevention of cardiovascular complications in patients with CHD. Phys. 2013; 12: 40–41.
  27. Bularga A., Chapman A.R., Mills N.L. Mechanisms of Myocardial Injury in COVID-19. Clin Chem. 2021;67(8):1044–1046. doi: 10.1093/clinchem/hvab111.
  28. Dedov DV, Ivanov AP, Elgardt IA Risk of recurrence of atrial fibrillation in patients with coronary heart disease and arterial hypertension according to Holter electrocardiogram monitoring. Bulletin of Arrhythmology. 2010; 59: 27–32.
  29. Huang C., Wang Y., Li X. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506. doi: 10.1016/S0140-6736(20)30183-5.
  30. Singh S., Offringa-Hup A.K., Logtenberg S.J.J. et al. Discontinuation of Antihypertensive Medications on the Outcome of Hospitalized Patients with Severe Acute Respiratory Syndrome-Coronavirus 2. Hypertension. 2021;78(1):165–173. doi: 10.1161/Hypertensionaha.121.17328.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download
2. Fig.1

Download (219KB)
Indexing metadata

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies